How to Manage GLP-1 Side Effects: Practical Strategies That Work

Starting a GLP-1 medication like semaglutide or tirzepatide is a meaningful step. Most people tolerate these medications well over time, but the first few weeks and months can bring side effects that feel discouraging if you don't know what to expect or what to do.

The good news is that most GLP-1 side effects are manageable. They peak during the titration phase, typically the first four to twelve weeks, and then ease significantly for the majority of people as the body adjusts. Understanding what's happening and why gives you the tools to get through that window without unnecessary suffering.

This guide covers the most common side effects and what you can actually do about them.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects FDA-approved branded products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

Why GLP-1 Medications Cause Side Effects

GLP-1 receptors are found throughout the body, and a significant concentration of them lines the gastrointestinal tract. When a GLP-1 receptor agonist activates those receptors, the gut responds by slowing down. Gastric emptying, the rate at which food moves from the stomach into the small intestine, decreases. This is part of what makes these medications so effective for weight management: food stays in your stomach longer, which extends the feeling of fullness and reduces appetite.

The downside of that same mechanism is nausea, bloating, and the other GI complaints that come with slowed motility. A 2025 review in Current Gastroenterology Reports confirmed that delayed gastric emptying is the primary driver of GLP-1-related GI effects and that these effects are dose-dependent, meaning they tend to be most pronounced when doses are highest or when doses are being increased (PMID 40622491).

This is why the titration schedule matters so much. Both semaglutide and tirzepatide are started at low doses and increased gradually over months, specifically to give the GI tract time to adapt before the dose climbs higher.

In the STEP 1 clinical trial, nausea was the most frequently reported adverse event among participants taking weekly semaglutide 2.4mg for obesity. Most cases were mild to moderate in severity, and the highest rates of GI symptoms occurred during the dose escalation period rather than at stable dosing (PMID 33567185). The SURMOUNT-1 trial for tirzepatide found a similar pattern: GI adverse events were most common during titration and declined substantially as participants reached and stabilized at their target dose (PMID 37129833).

That pattern is worth remembering when side effects feel difficult. The worst stretch is usually temporary.

---

Managing Nausea

Nausea is the side effect people ask about most, and it is also the one with the most practical levers to pull.

Eat smaller portions. A stomach that is deliberately slowing its emptying does not tolerate large meals well. Many people find that reducing portion sizes by roughly a third during the titration period makes a substantial difference. You may also find your appetite guiding you there naturally, as satiety signals arrive faster than they used to.

Avoid high-fat, fried, and spicy foods. High-fat meals already slow gastric emptying on their own. When combined with GLP-1 therapy, the compounding effect can intensify nausea significantly. During the first few months, lean proteins, vegetables, and whole grains tend to be much better tolerated than rich or heavily seasoned foods.

Don't eat too quickly. Eating fast sends a large volume of food to a stomach that is already working in slow motion. Chewing thoroughly and pausing between bites gives your gut time to process each portion before the next one arrives.

Stay upright after eating. Lying down within 60 to 90 minutes of a meal traps food against the gastroesophageal junction and worsens GI symptoms. Even light movement, like a short walk, helps move things along.

Try ginger. Ginger tea, ginger chews, and ginger capsules have a well-established role in managing nausea generally, and many people report them helpful with GLP-1-related nausea. Clinical evidence specific to GLP-1 therapy is limited, but ginger carries minimal risk and is worth trying.

Drink cool or room-temperature fluids. Hot liquids can aggravate nausea for some people. Cool water or electrolyte drinks between meals, rather than with them, tend to be better tolerated.

Talk to your provider about the titration pace. If nausea is significantly affecting your daily life, slowing down the titration, staying at a lower dose for an extra four weeks before stepping up, is a legitimate and commonly used strategy. You do not need to push through severe symptoms. The goal is to find the dose your body can sustain, not the fastest route to the maximum dose.

---

Managing Constipation

Slowed gut motility means food moves more slowly through the entire digestive tract, not just the stomach. For many people, the result is constipation, particularly during the first few months.

Increase dietary fiber. Aim for 25 to 38 grams of fiber per day from food sources like vegetables, beans, lentils, whole grains, and fruit. Increase gradually to avoid worsening bloating as you scale up.

Drink more water. Fiber absorbs water as it moves through the gut, so hydration is essential for it to work correctly. Most people benefit from 8 to 10 cups of water daily, and more if they are exercising.

Move your body. Physical activity directly stimulates intestinal motility. A 20-minute walk after meals is one of the most consistent and low-effort interventions for constipation.

Consider a fiber supplement. Psyllium husk, taken with a full glass of water, is a widely used, evidence-supported option. Start with a small amount and increase slowly over one to two weeks.

If constipation is persistent or uncomfortable despite these measures, talk to your provider. They may recommend a short-term stool softener or osmotic laxative to bridge the adjustment period.

---

Managing Diarrhea and Loose Stools

Diarrhea is less common than constipation but does occur, particularly in the early weeks or when doses are increased.

Stay hydrated. Fluid and electrolyte replacement is the priority. Water, diluted sports drinks, or oral rehydration solutions help. Avoid caffeinated beverages, which can worsen GI motility.

Eat bland foods during flares. During a diarrhea episode, stick to easily digested foods like rice, boiled chicken, toast, bananas, or applesauce. Avoid high-fiber, high-fat, and spicy foods temporarily.

Limit alcohol. Alcohol speeds GI motility and should be avoided or minimized when symptoms are active.

Most diarrhea related to GLP-1 initiation resolves on its own within a few days. If it is severe, lasts more than a week, or is accompanied by fever or blood in the stool, contact your provider promptly.

---

Fatigue and Headache in the Early Weeks

Some people experience fatigue or mild headaches in the first weeks of treatment, especially around dose increases. These are most often tied to reduced caloric intake rather than to the medication acting directly on energy pathways.

Don't cut calories too aggressively. GLP-1 medications suppress appetite powerfully, and some people inadvertently drop their food intake far below what their body needs to function. Eating regular meals on a schedule, even when appetite is low, helps maintain energy levels. Prioritize protein and vegetables, which are nutrient-dense and well tolerated.

Track fluid intake. Reduced appetite often means reduced fluid intake as well. Dehydration is a common and under-recognized cause of headaches in people starting GLP-1 therapy.

Prioritize sleep. The metabolic shift that comes with significant caloric reduction can affect sleep quality in some people. Consistent sleep and wake times help regulate this.

Fatigue and headache symptoms typically improve within the first four to six weeks as the body adapts.

---

Injection Site Reactions

Injection site reactions, including temporary redness, bruising, mild swelling, or itching at the injection site, are common with subcutaneous injectable medications.

Rotate your injection sites systematically. Use the approved injection zones, which typically include the abdomen, outer thigh, and upper arm, rotating through different locations each week. Injecting repeatedly into the same spot can cause lipohypertrophy, a buildup of fatty tissue that affects how the medication is absorbed.

Let the medication warm to room temperature before injecting. Cold medication from the refrigerator is more likely to cause discomfort and irritation. Letting the pen sit for 15 to 30 minutes before use makes a noticeable difference for most people.

Inject slowly. A slow, steady press of the injection button is more comfortable than a fast push.

Most injection site reactions are mild and resolve within one to two days.

---

Hair Thinning: What Is Actually Happening

Hair thinning is a real and documented experience for some people on GLP-1 therapy, and it tends to cause significant worry. The mechanism is worth understanding, because the context changes how alarming it feels.

A 2025 review published in Skin Appendage Disorders found that hair loss associated with GLP-1 receptor agonists is primarily a form of telogen effluvium: a stress-triggered shedding in which a significant number of hair follicles shift from the growth phase to the resting phase simultaneously (PMID 41058954). The trigger in this case is not the medication acting on hair follicles directly. It is the significant caloric reduction and metabolic stress that comes with rapid weight loss. The same pattern occurs after bariatric surgery, during severe illness, and with other forms of acute caloric restriction.

A 2026 review in the Journal of the American Academy of Dermatology also identified alopecia as an adverse event associated with GLP-1 therapy in clinical practice, while noting that the relative contribution of direct medication effects versus weight-loss-related stress requires further study (PMID 41698604).

What this means practically:

• Hair thinning typically begins two to four months after weight loss accelerates and often peaks around four to six months.
• For most people, shedding resolves on its own within six to twelve months as the body stabilizes at a new weight.
• Adequate protein intake, roughly 0.7 to 1.0 gram per pound of body weight per day, is the most consistently recommended strategy to reduce severity.
• Biotin supplements are widely used and considered harmless, though clinical evidence for their effectiveness specifically in telogen effluvium is limited.

If hair thinning is significant or accompanied by other symptoms like fatigue, cold intolerance, or changes in your menstrual cycle, ask your provider about thyroid function and nutritional labs. Nutrient deficiencies and thyroid changes can compound weight-loss-related hair loss.

---

When to Contact Your Provider

Most GLP-1 side effects are manageable at home and will improve over time. Some symptoms require a prompt conversation with your provider rather than home management.

Reach out if:

• Nausea or vomiting is severe, lasting more than one week, or preventing adequate hydration
• You are unable to keep fluids down
• You have significant or worsening abdominal pain, especially in the upper abdomen or radiating to the back (rare but possible indicators of pancreatitis or gallbladder issues)
• You notice vision changes
• Your resting heart rate feels consistently elevated beyond what is typical for you
• Injection site redness, swelling, or pain is spreading or worsening after 48 hours

Seek emergency care immediately for chest pain, difficulty breathing, or signs of a severe allergic reaction such as facial swelling, widespread hives, or throat tightness.

---

Working With Your Dosing Schedule

The graduated titration schedule for GLP-1 medications is not arbitrary. It reflects how the body adapts to receptor activation over time. Each dose increase represents a new adaptation period. Moving through that process too quickly intensifies side effects without improving outcomes.

If you are struggling with side effects, the most important conversation to have is with your provider about pacing. Staying at a lower dose for an additional four weeks, or even returning temporarily to a lower dose after a difficult increase, is a legitimate clinical decision. Many people end up tolerating their target dose well once they find the right path to get there.

Do not adjust your dose schedule without provider guidance. But do communicate clearly about how you are feeling. Providers cannot help you troubleshoot what they don't know is happening.

The side effect window is real, but it is also time-limited. Most people who work through it reach a place where GLP-1 therapy is well tolerated and effective. Understanding the mechanisms and the practical strategies is what makes that transition possible.

---

*This article is for educational and informational purposes only and does not constitute medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Always consult your licensed healthcare provider before starting, stopping, or adjusting any medication or supplement. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

Ready to explore your options? [Check your eligibility](https://prescriva.com/start) to connect with a licensed provider who can guide you through your treatment.

---

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022;387(3):205-216. [PMID 37129833](https://pubmed.ncbi.nlm.nih.gov/37129833/)

1. Bellavance J, et al. GLP-1 Receptor Agonists and Gastrointestinal Motility. *Curr Gastroenterol Rep.* 2025. [PMID 40622491](https://pubmed.ncbi.nlm.nih.gov/40622491/)

1. Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. *Skin Appendage Disord.* 2025;11(5):416-423. [PMID 41058954](https://pubmed.ncbi.nlm.nih.gov/41058954/)

1. Narla S, Narla RR. JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology. *J Am Acad Dermatol.* 2026. [PMID 41698604](https://pubmed.ncbi.nlm.nih.gov/41698604/)